- Home
- KOS vs GERN Comparison
KOS vs GERN Comparison
Compare KOS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- GERN
- Stock Information
- Founded
- KOS 2003
- GERN 1990
- Country
- KOS United States
- GERN United States
- Employees
- KOS N/A
- GERN N/A
- Industry
- KOS Oil & Gas Production
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- KOS Energy
- GERN Health Care
- Exchange
- KOS Nasdaq
- GERN Nasdaq
- Market Cap
- KOS 698.3M
- GERN 823.0M
- IPO Year
- KOS 2011
- GERN 1996
- Fundamental
- Price
- KOS $1.67
- GERN $1.24
- Analyst Decision
- KOS Hold
- GERN Buy
- Analyst Count
- KOS 5
- GERN 7
- Target Price
- KOS $3.40
- GERN $3.17
- AVG Volume (30 Days)
- KOS 10.0M
- GERN 7.2M
- Earning Date
- KOS 11-03-2025
- GERN 11-06-2025
- Dividend Yield
- KOS N/A
- GERN N/A
- EPS Growth
- KOS N/A
- GERN N/A
- EPS
- KOS N/A
- GERN N/A
- Revenue
- KOS $1,488,836,000.00
- GERN $164,447,000.00
- Revenue This Year
- KOS N/A
- GERN $172.62
- Revenue Next Year
- KOS $15.84
- GERN $56.87
- P/E Ratio
- KOS N/A
- GERN N/A
- Revenue Growth
- KOS N/A
- GERN 11877.20
- 52 Week Low
- KOS $1.39
- GERN $1.09
- 52 Week High
- KOS $4.22
- GERN $4.50
- Technical
- Relative Strength Index (RSI)
- KOS 52.21
- GERN 43.70
- Support Level
- KOS $1.41
- GERN $1.19
- Resistance Level
- KOS $1.51
- GERN $1.31
- Average True Range (ATR)
- KOS 0.09
- GERN 0.07
- MACD
- KOS 0.00
- GERN -0.01
- Stochastic Oscillator
- KOS 56.67
- GERN 17.31
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.